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INTRODUCTION
Recombinant adeno-associated virus (rAAV) is an attractive tool for 
gene transfer and has emerged as a versatile and leading delivery 
vector for gene therapy.1–3 Although rAAV can safely transfer thera-
peutic genes into dividing and nondividing cells in vivo, the conven-
tional methods for rAAV production are associated with many chal-
lenges. In order to use vectors for in vivo gene transduction, the final 
product of rAAV should contain minimum impurities and empty 
particles, thus requiring simple purification processes for large-scale 
production. However, the conventional methods for the produc-
tion and purification of rAAV from the cell lysate fractions of trans-
fected human embryonic kidney-derived 293 (HEK293) cells entail 
cumbersome procedures. In addition, purification methods using 
cesium chloride (CsCl) or iodixanol density  ultracentrifugation4,5 
are not suitable for large-scale production. Therefore, development 
of alternative methods is required in order to use rAAV in clinical 
practice.
Chromatography-based systems are scalable while ultracentrifuga-
tion-based methods are not. In this regard, we used the serum-free 
culture supernatant of triple-transfected HEK293 cells, as opposed 
to the cell lysate fraction, as starting material for a chromatography 
procedure (ion-exchange or gel-filtration chromatography). There 
are several reports of chromatography-based methods for purifica-
tion, which have mostly used ion-exchange6–10 and affinity chroma-
tography.11–14 However, it is difficult to separate the particles of the 
viral genome from the empty particles using affinity chromatog-
raphy techniques. Since the isoelectric points of vector particles 
(capsid proteins) are different in the presence or absence of vector 
genomes, it is more advisable to use ion-exchange chromatography. 
Consequently, rAAV serotype 1 (rAAV1) can be separated from the 
ion-exchange crude products on the basis of molecular size, using 
size-exclusion chromatography (gel-filtration chromatography). We 
previously reported that the viral genome particles could be effec-
tively separated with the use of dual ion-exchange column configu-
ration (cationic/anionic ion-exchange adsorptive membranes) chro-
matography, after partial purification of the cell lysate fractions of 
transfected HEK293 cells with step density gradient centrifugation.7 
This method is useful depending on the physiological characteristics 
of a particular capsid of a serotype vector. Since there is generally a 
substantial amount of cell-derived contaminating protein from the 
cell lysate, for clinical applications, it is advisable to use the serum-free 
culture supernatant. Therefore, as the next stage of our research on 
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Recombinant adeno-associated virus (rAAV) is an attractive tool for gene transfer and shows potential for use in human gene  therapies. 
The current methods for the production and purification of rAAV from the transfected cell lysate are mainly based on cesium chloride 
and iodixanol density ultracentrifugation, although those are not scalable. Meanwhile, chromatography-based  systems are more 
scalable. Therefore, in this study, we developed a novel method for the production and purification of rAAV serotype 1 (rAAV1) from 
serum-free culture supernatant based on ion-exchange and gel-filtration chromatography to obtain highly purified products with an 
ultracentrifugation-free technique towards Good Manufacturing Practice (GMP) production. The purified rAAV1 displayed three clear 
and sharp bands (VP1, VP2, and VP3) following sodium dodecyl sulfate–polyacrylamide gel electrophoresis, and more than 90% of 
rAAV1 particles contained fully packaged viral genomes according to negative-stain electron micrographic analysis. Consequently, the 
resultant genomic titer of the purified rAAV1 was 3.63 × 1013 v.g./ml (the total titer was 4.17 × 1013 v.g.) from the 4 × 109 HEK293 cells. This 
novel chromatography-based method will facilitate scale-up of manufacturing for clinical applications in gene therapy.
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the development of new techniques for the large-scale production 
and purification of rAAV1, we referred to ion-exchange technology.
rAAV1 can transduce the skeletal muscles more efficiently than 
other serotypes and is thus considered to be a promising therapeu-
tic vector.15 Furthermore, Glybera (alipogene tiparvovec), the first 
rAAV-based drug to receive official approval from the European 
Medicines Agency, was produced from rAAV1.16 In this study, we 
evaluated the potential for large-scale purification of rAAV1 from 
the serum-free culture supernatant using ion-exchange and gel-
filtration chromatography-based methods with an ultracentrifuga-
tion-free technique, with the goal of Good Manufacturing Practice 
(GMP)-level production.
ReSUlTS
Ammonium sulfate precipitation
We used ammonium sulfate (AS) precipitation treatment as rAAV1 
semi-purification procedure after the culture supernatant was ultra-
filtrated with tangential flow filtration (TFF) and concentrated about 
10 times, using a hollow fiber. Although half-saturated (1/2) AS pre-
cipitation is a conventional procedure, Figure 1 shows that two-step 
precipitation with both 1/3- and 1/2-saturated AS precipitation treat-
ment was superior to the procedure with only the 1/2-saturated treat-
ment in terms of purity on sodium dodecyl sulfate–polyacrylamide 
gel electrophoresis (SDS–PAGE) analysis (Quick Coomassie Brilliant 
Blue staining, Wako, Osaka, Japan). After reducing protein debris 
by 1/3-saturated AS precipitation (adding half the sample volume 
of saturated AS made the final solution 33% (NH4)2SO4), rAAV1 was 
finally precipitated in the 1/2-saturated AS solution (added half the 
original sample volume of saturated AS) (1/3→1/2 AS). The first 
1/3-saturated AS precipitation served to remove the contaminants. 
The second 1/2-saturated AS precipitation resulted in the precipitate 
and concentrated rAAV1. Both viral genomic titer of 1/3→1/2 AS and 
1/2 AS was nearly equal (data not shown).
Various methods attempted to remove 200 kDa protein impurities
Three plasmids (the cis AAV vector plasmid, trans-plasmid, and 
adenovirus helper plasmid) were transfected to HEK293 cells 
with polyethyleneimine (Polyethyleneimine Max, Polysciences, 
Warrington, PA) in serum-free medium. After harvesting culture 
supernatant, the supernatant was ultrafiltrated with TFF with 
the hollow fiber using the KrosFlo Research IIi system (Spectrum 
Laboratories, Rancho Dominguez, CA) and precipitated by 
1/3→1/2 AS. After 1/3→1/2 AS, the sample was dissolved in 3.3 
mmol/l morpholinoethanesulfonic acid, 3.3 mmol/l HEPES, and 
3.3 mmol/l sodium acetate (MHN) buffer (pH 6.5) containing 50 
mmol/l NaCl and 0.01% Pluronic F-68 (Gibco, Invitrogen, Grand 
Island, NY) and was loaded onto the dual ion-exchange column 
configuration (cationic: Mustang SXT; anionic: Mustang QXT, Pall 
Corporation, Ann Arbor, MI) chromatography. First, the tandem 
two Mustang SXTs were used to remove empty particles, and 
then, tandem two Mustang QXTs were used for absorbing fully 
packaged rAAV1 particles. The sample was then eluted from the 
Mustang QXTs by stepwise NaCl gradient elution (50–158 and 
158–275 mmol/l NaCl in 3.3 mmol/l MHN buffer, pH 8.0, with 
0.01% Pluronic F-68) (Supplementary Figure S1a,b). After ultra-
filtration with Ultracel 30 K (nominal molecular weight cutoff 
30 K, Merck Millipore, Tullagreen, Ireland), rAAV1 was finally puri-
fied by gel-filtration chromatography on Superdex 200 Increase 
10/300 GL (GE Healthcare, Uppsala, Sweden) using the AKTÄ 
Explorer 100 HPLC system (the chromatogram results are shown 
in Supplementary Figure S1c,d). However, when the sample was 
loaded onto the ion-exchange columns in a buffer containing 
50 mmol/l NaCl, the 200 kDa protein impurities could not be 
removed (Figure 2; Supplementary Figure S1e).
Therefore, we tested various methods to find the most effective 
way to remove these impurities, which are shown in Figure 3; all 
methods were assayed immediately after the sample was ultrafil-
trated with the TFF (post-TFF preparation). First, the sample was 
heated at 50 °C for 20 minutes. The low-molecular-weight molecules 
could be removed, but the 200 kDa protein impurities could not be 
removed (Figure 3a). Nevertheless, this heat treatment resulted in a 
higher purity with no reduction of yield (data not shown); therefore, 
this procedure was integrated into the overall purification protocol. 
Second, the sample was ultrafiltrated by Vivaspin 6 300,000 MWCO 
PES or 1000,000 MWCO PES (Figure 3b; Sartorius AG, Gӧttingen, 
Germany). Neither the impurities nor rAAV1 were ultrafiltrated, so 
that the impurities could not be removed with this procedure. Next, 
we tried to precipitate the rAAV1 with acetone (Figure 3c). After pre-
cipitating the proteins (rAAV1 and the impurities) with acetone, the 
precipitate was dissolved in phosphate-buffered saline (PBS). We 
expected that rAAV1 would be soluble in PBS while the impurities 
would be denatured. However, all of the proteins dissolved in PBS 
and therefore could not be separated with this method. Finally, we 
attempted Novec 7100 (methoxy-nonafluorobutane, C4F9OCH3, 3M, 
St. Paul, MN) treatment (Figure 3d). Similar to the heat treatment, 
the low-molecular-weight proteins were removed but the impuri-
ties could not be removed.
Figure 1 Improved purity of the culture supernatant with ammonium 
sulfate (AS) precipitation. Half-saturated AS (1/2 AS) precipitation was 
applied as the conventional procedure (Lane 3, the left black square). 
After reducing the amount of protein debris by 1/3-saturated AS 
precipitation, recombinant adeno-associated virus serotype 1 was 
finally precipitated in 1/2 AS solution (1/3→1/2 AS), which is our novel 
protocol (Lane 5, the right black square). The samples were analyzed 
by 5–20% gradient sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis (SDS-PAGE) gel (Quick Coomassie Brilliant Blue staining). 
Lane 1: pre-tangential flow filtration (pre-TFF); Lane 2: post-TFF; Lane 3: 
post-TFF preparation was directly precipitated in 1/2 AS; Lane 4: 1/3 AS 
precipitation; Lane 5: 1/3→1/2 AS; M: protein size marker.
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Purification by ion-exchange and gel-filtration chromatography 
with a buffer containing 5 mmol/l NaCl
After the post-TFF preparation from 4 × 109 HEK293 cells was par-
tially purified by 1/3→1/2 AS, we attempted to dialyze the sample 
against a low-salt buffer containing 5 mmol/l NaCl and 3 mmol/l 
MgCl2 and load it onto the tandem dual five cation-exchange col-
umns and the five anion-exchange columns configuration with low 
ionic strength to remove the impurities. The resultants purified by 
the ion-exchange columns are shown in Figure 4a. We successfully 
removed the impurities using this method.
The sample was dialyzed against a low-salt concentration buffer 
containing 5 mmol/l NaCl and 3 mmol/l MgCl2, which was added to the 
buffer to stabilize the rAAV.17 The dialyzed sample was loaded onto the 
tandem dual five Mustang SXTs (to remove the empty particles) and 
the five Mustang QXTs (to absorb rAAV1). As shown in Figure 4a, the 
rAAV1 was mainly eluted by 120 mmol/l NaCl buffer from the Mustang 
QXTs, and the 200 kDa protein impurities were excluded by the 200 
mmol/l NaCl buffer. The sample eluted by 120 mmol/l NaCl buffer and 
the first 40 ml of the sample eluted by 130 mmol/l NaCl buffer were 
collected and ultrafiltrated with Ultracel 30 K. We also eluted the rAAV1 
with 160, 180, and 200 mmol/l NaCl-containing buffer. Although addi-
tional rAAV1 was eluted, it contains a lot of contaminated proteins and 
there was very few amount of rAAV1. The fractions in the black square 
on Figure 4a were ultrafiltrated with Ultracel 30 K and gel-filtrated 
by the Superdex 200 10/300 GL column (GE Healthcare, Uppsala, 
Sweden) (Figure 4b). The first peak represents elution of rAAV1 (black 
arrowhead) and the second peak represents elution of the ~65 kDa 
Figure 2 Purification with a buffer containing 50 mmol/l NaCl. 
(a)  Recombinant adeno-associated virus serotype 1 (rAAV1) purified 
by ion-exchange column with a buffer containing 50 mmol/l NaCl was 
analyzed by 5–20% gradient sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis (SDS-PAGE) gel (Oriole staining) and (b) western blotting. 
M: protein size marker. The 200 kDa protein impurities were still present 
(white triangle) and the purity was low. The three rAAV1 capsid proteins, 
VP1 (81.4 kDa), VP2 (66.2 kDa), and VP3 (59.6 kDa), were represented.
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Figure 3 Various methods were attempted to remove 200 kDa protein impurities to obtain a pure sample. All methods were assayed with post-
tangential flow filtration (post-TFF) preparation using 5–20% gradient sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) gel 
(Quick Coomassie Brilliant Blue staining). None of these methods was effective for removing the 200 kDa protein impurities (white triangles). (a) 
Samples were heated at 50 °C for 20 minutes. Lane 1: pre-TFF; Lane 2: post-TFF; Lane 3: heat-treated post-TFF preparation; M: protein size marker. The 
star shows that the low-molecular-weight impurities were removed. (b) Samples were ultrafiltrated by Vivaspin 6 300,000 MWCO PES and 1000,000 
MWCO PES (Sartorius AG, Gӧttingen, Germany). Lane 1: pre-TFF; Lane 2: post-TFF; Lane 3: fraction passed through Vivaspin 6 300,000 MWCO PES; 
Lane 4: concentrated with Vivaspin 6 300,000 MWCO PES; Lane 5: fraction passed through Vivaspin 6 or 1000,000 MWCO PES; Lane 6: concentrated 
with Vivaspin® 6 or 1000,000 MWCO PES; M: protein size marker. (c) Samples were precipitated by acetone. Lane 1: pre-TFF; Lane 2: post-TFF; Lane 3: 
precipitated by acetone and dissolved in phosphate-buffered saline; Lane 4: supernatant of acetone precipitation; M: protein size marker. (d) Samples 
were treated with Novec 7100. Lane 1: pre-TFF; Lane 2: post-TFF; Lane 3: the water layer of Novec treatment; Lane 4: the middle layer of Novec treatment; 
M: protein size marker. The star shows the same as (a).
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protein impurities (gray arrowhead). As shown in Figure 4c, three clear 
and sharp bands (VP1 (81.4 kDa), VP2 (66.2 kDa), and VP3 (59.6 kDa)) 
represented the product of rAAV1 obtained by gel-filtration chroma-
tography with high purity on SDS–PAGE (Oriole staining). Peak frac-
tions at the black square on Figure 4c were collected and concentrated 
by Ultracel 30 K to obtain the final product (Figure 4d). The high purity 
of rAAV1 was confirmed by SDS–PAGE (98% of intensity by Image J 
program analysis), the protein staining with Oriole (BIO-RAD, Hercules, 
CA), and western blotting using anti-AAV capsid-monoclonal antibody 
(B1, Progen, Heidelberg, Germany) (Figure 4e).
Characteristics of rAAV1
We analyzed the empty particle contamination and infectiv-
ity of rAAV1 with electron microscopy (negative staining) and 
fluorescence-activated cell sorting, respectively, to verify its qual-
ity. More than 90% of the rAAV1 particles contained viral vector 
genomes, as observed by electron micrographic analysis (Figure 4f). 
We titrated the rAAV1 at a point where 2.0 × 105 cells of C2C12 were 
transduced with rAAV1 at 0.5, 0.7, and 2.0 × 105 v.g./cell (Table 1). We 
compared the infectivity directly with rAAV1s before and after chro-
matography-based purification. We confirmed increasing infectivity 
of rAAV1 product depending on chromatographic purification step. 
Both population of EGFP-positive cells and intensity of EGFP expres-
sion were improved at all condition (Table 1). Furthermore, this obser-
vation supports the high percentage of fully packaged viral genomes 
by electron microscopic analysis. The resultant genomic titer of the 
purified rAAV1 was 3.63 × 1013 v.g./ml (the total titer was 4.17 × 1013 
v.g.) from the 4 × 109 HEK293 cells, suggesting that the purified rAAV1 
Figure 4 Effects of chromatography-based purification of recombinant adeno-associated virus serotype 1 (rAAV1). (a) rAAV1 eluted from the five 
Mustang QXTs (anion-exchange column) by stepwise NaCl gradient elution was analyzed by 5–20% gradient sodium dodecyl sulfate–polyacrylamide 
gel electrophoresis (SDS–PAGE) gel (Oriole staining). The black square indicates the fractions loaded on Superdex 200 10/300 GL at next gel-filtration 
chromatography step. The white triangle indicates the 200 kDa protein impurities. Lane 1: after dialysis; Lanes 2–4: eluted by 100 mmol/l NaCl; Lanes 5–7: 
eluted by 120 mmol/l NaCl; Lanes 8–10: eluted by 130 mmol/l NaCl; Lanes 11–13: eluted by 140 mmol/l NaCl; Lanes 14–16: eluted by 200 mmol/l NaCl; 
M: protein size marker. (b,c) The samples were subsequently gel-filtrated by the Superdex 200 10/300 GL column and elution fractions were analyzed by 
5–20% gradient SDS–PAGE (Oriole staining). (b) Elution pattern of Superdex 200 10/300 GL. The y-axis: 280 nm absorbance; x-axis: fraction number. The 
black triangle indicates the peak fractions of rAAV1 (corresponding to the black square on (c)) and the gray arrowhead indicates ~65 kDa protein impurities. 
(c) Elution fractions analyzed by 5–20% gradient SDS–PAGE gel (Oriole staining). Lane 1: after dialysis; Lanes 2–11: Fr 13–22; Lane 12: Fr 27; M: protein size 
marker. The gray arrowhead shows the same as (b). (d–f) Peak fractions (the black square on (c)) were collected and concentrated by Ultracel 30 K to obtain 
the final product. (d) The final product of rAAV1 was analyzed by 5–20% gradient SDS–PAGE gel (Oriole staining), (e) western blotting, and (f) electron 
microscopy (negative staining). M: protein size marker. The three rAAV1 capsid proteins, VP1 (81.4 kDa), VP2 (66.2 kDa), and VP3 (59.6 kDa), were represented.
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corresponded to about 1 × 104 v.g. per cell. These results suggest that 
functional rAAV1 with high purity could be obtained using our new 
protocol.
A schematic representation of the processes for rAAV1 produc-
tion and purification is finally shown in Figure 5.
Comparison of the purity of rAAV1 obtained from 
ultracentrifugation and chromatography-based purification
The comparison of the purity of rAAV1 obtained from the ultracentrifu-
gation and chromatography steps with SDS–PAGE is shown in Figure 
6. The ultracentrifugation was performed using an iodixanol linear 
gradient operation after 1/2-saturated AS precipitation. The rAAV1 
purified by ultracentrifugation was stained with Quick Coomassie 
Brilliant Blue, and that purified by this novel chromatography-based 
protocol was stained with Oriole Fluorescent Gel Stain. The sensitivity 
of the Oriole stain is almost equal to that of silver staining. The black 
square on Figure 6a shows the peak fractions of rAAV1 purified by 
iodixanol density ultracentrifugation. The results show that the purity 
of rAAV1 processed by chromatography steps was equal to or higher 
than that processed by ultracentrifugation (Figure 6).
DISCUSSION
In this study, we tried to produce and purify rAAV1 from serum-free 
culture supernatant and chromatography (dual ion-exchange and 
gel-filtration chromatography) in order to avoid the disadvantages 
associated with purification using the ultracentrifugation tech-
nique. We took advantage of the fact that a good yield of rAAV1 
can be obtained directly in the culture supernatant18 and the cul-
ture supernatant has vector-containing sample with higher purity 
than cell lysate from the point of view of proteins contamination, 
and we finally obtained highly purified and functional rAAV1 with 
an ultracentrifugation-free technique from the culture supernatant. 
Our large-scale method for the purification of rAAV1 from the cul-
ture supernatant using an ultracentrifugation-free technique for 
GMP-grade production is the first such protocol and thus represents 
a breakthrough in the field.
There are several reports related to the production and purifica-
tion of rAAV1.7,10,19–21 Zolotukhin et al.10 reported the purification of 
rAAV1 from the cell lysate using iodixanol gradient ultracentrifuga-
tion and anion-exchange chromatography. To minimize impurities, 
the use of the culture supernatant has many advantages. Indeed, 
we previously reported7 a method for the ion-exchange (Mustang 
S + Mustang Q) chromatography purification of rAAV1 from the 
culture supernatant. We demonstrated the successful large-scale 
purification of rAAV1 using CsCl ultracentrifugation for the first 
concentration step. Vandenberghe et al.20 and Lock et al.19 reported 
rAAV1 purification from the serum-free culture medium. In addition 
to the purification of rAAV1 by CsCl or iodixanol ultracentrifugation, 
they did not purify it at the large scale. Furthermore, Smith et al.21 
reported one-step affinity chromatography purification of rAAV1 
from the baculovirus-AAV expression vector system. Although they 
purified high-titer rAAV1 without using the ultracentrifugation 
technique, we consider the baculovirus system to be problematic. 
Recently, a novel rhabdovirus was found in Spodoptera frugiperda 
(Sf9) cell lines.22 Furthermore, the glycoproteins produced in insect 
cells are different from those of mammalian cells, which may ulti-
mately affect the biological function of rAAV in terms of glycosyl-
ation23 and lead to immunorejection in humans. In this context, 
human cells (HEK293 cells) are preferable for producing rAAV1 com-
pared to the baculovirus system. There has been no previous report 
about the large-scale purification of rAAV1 from the serum-free cul-
ture supernatant to avoid the ultracentrifugation technique toward 
GMP production. Taken together, our present study represents an 
innovative method for rAAV1 purification and valuable.
Smith et al.24 reported the rAAV1 purification method using a low-
salt buffer. In this study, rAAV1 was harvested from the cell lysate 
Table 1 Infectious titer measured by FACS
C2C12 2 × 105 cells
Sample 5 × 104 7 × 104 2 × 105
Final product 11.61% 15.13% 39.82% 
(6.71) (7.85) (18.28)
Post-TFF preparation 8.99% 12.78% 38.55% 
(5.68) (6.80) (16.99)
The 2.0 × 105 of C2C12 cells were transduced with recombinant adeno-
associated virus serotype 1 (rAAV1) at 0.5, 0.7, and 2.0 × 105 v.g./cell. 
Population of EGFP-positive cells as well as intensity was measured by 
FACS with propidium iodide staining solution to remove nonviable cells. 
The upper row is the population of the EGFP-positive cells (%) and the 
lower row is intensity. C2C12 cells were transduced with rAAV1s before 
and after chromatography-based purification. Upper row; population of 
EGFP-positive cells (%). Lower row: intensity of EGFP expression. FACS, 
fluorescence-activated cell sorting; TFF, tangential flow filtration.
Figure 5 Schematic representation of the recombinant adeno-associated 
virus serotype 1 (rAAV1) production and purification procedure. Three 
plasmids (the cis AAV vector plasmid, trans-plasmid, and helper plasmid) 
were transfected to HEK293 cells with PEI (Polyethyleneimine Max) in 
serum-free medium. After harvesting the culture supernatant, it was 
ultrafiltrated with TFF using the hollow fiber using the KrosFlo Research 
IIi system. After reducing the amount of protein debris by 1/3-saturated 
AS precipitation, rAAV1 was finally precipitated in 1/2-saturated AS 
solution (1/3→1/2 AS). Then, it was dialyzed against a low-salt buffer 
(containing 5 mmol/l NaCl) and absorbed to ion-exchange membranes. 
Finally, rAAV1 eluted from the anion-exchange column was purified by 
gel-filtration chromatography. AS, ammonium sulfate; FCS, fetal calf 
serum; PEI, polyethyleneimine.
PEI
(FCS-free)
HEK293 cells
(harvest culture supernatant, pre-TFF)
Ion exchange
(Mustang SXT/QXT)
Gel filtration
(Superdex 200 10/300 GL)
3 plasmids
Final product 
TFF
(Post-TFF preparation)
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and purified using SOURCE15Q, a bead-based anion-exchange 
chromatography column. Although a good yield of rAAV1 can be 
obtained in the culture supernatant,18,20 there is nonetheless a sub-
stantial amount of impurities derived from the cells when purified 
from the cell lysate. Therefore, we purified rAAV1 from the culture 
medium. Compared to SOURCE15Q, Mustang columns reduce the 
bed volume and purification procedure for rAAV and involve sim-
pler processes with respect to equilibration, sample loading, wash-
ing, and elution. Therefore, the use of membrane adsorbers such 
as Mustang columns also saves time and cost. The 200 kDa protein 
impurities were hard to remove by various methods but efficiently 
removed by using the low-salt concentration buffer. However, the 
specific characteristics of the 200 kDa protein impurities were not 
identified. Therefore, further investigations should be conducted to 
determine exactly what these impurities are and why the low-salt 
buffer can effectively remove them. A potential way to approach 
this question is with mass spectrometry.
Elution pattern from ion-exchange column is influenced by the 
temperature.25 Purified by a buffer containing 50 mmol/l NaCl using 
AKTA (4 °C), rAAV1 was eluted by 158 mmol/l NaCl. Furthermore, 
in small scale, rAAV1 was mainly eluted by 140 mmol/l NaCl (21 °C) 
(data not shown). In double scale (main results of this article), rAAV1 
was mainly eluted by 120 mmol/l NaCl (14 °C). These indicate that 
temperature affects the ion-exchange column. Therefore, we eluted 
rAAV1 by stepwise NaCl gradient (100–200 mmol/l NaCl) where 
rAAV1 was eluted a certain concentration absolutely. Therefore, we 
would like to fix the temperature in future protocol.
This novel protocol produced a highly purified vector, which sug-
gests further scalability with our improved culture system using 
chemical defined medium and membrane capsule (e.g., Mustang 
QXT 5, Mustang QXT 140, or Mustang QXT 5000) and its applicabil-
ity to safe clinical investigations. It will need suspension cell system 
to produce rAAV in larger scale for clinical study. We believe that 
this purification method for rAAV1 secreted to serum-free medium 
is applicable to rAAV1 secreted to serum-free medium in suspen-
sion culture system. The median lethal dose (LD50) of CsCl in mice is 
910 µg/g of body weight for i.v. injection (“Safety data for caesium 
chloride”; http://msds.chem.ox.ac.uk/index2.html). So the CsCl-free 
and the ultracentrifugation-free method has very little risk of tox-
icity and is thus a suitable approach for the clinical use of rAAV1. 
Therefore, this streamlined method with a high-performance scal-
able ion-exchange membrane and gel-filtration chromatography 
should facilitate future clinical studies.
In summary, ion-exchange chromatography was used to success-
fully separate rAAV according to its isoelectric point. This suggests 
that different serotypes and vector genomes may show differences 
in absorption to an ion-exchange column. Thus, the purification of 
other serotypes without using ultracentrifugation should be inves-
tigated in the future.
MATeRIAlS AND MeTHODS
Cell culture
HEK293 cells (~4 × 109 cells in total) were plated in 22 square culture dishes 
(245 × 245 × 18 mm, 500 cm2; Corning, New York, NY) with a total surface 
area of 11,000 cm2. The cells were cultured in Dulbecco’s modified Eagle’s 
medium (Sigma-Aldrich, St. Louis, MO) with 8% fetal calf serum (Biowest, 
Nuaillé, France), penicillin, and streptomycin (Sigma-Aldrich, St. Louis, MO) 
at 37 °C in a 5% CO2 incubator for 2 days. 
Production of rAAV1
After the cells were grown to more than 90% confluence, they were trans-
fected with the cis AAV vector plasmid (with AAV-type 2 inverted terminal 
repeats), the trans-plasmid (with the AAV-type 2 Rep gene and the type 1 Cap 
gene; p5E18RXC1; a gift from James M. Wilson, University of Pennsylvania), 
and an adenovirus helper plasmid (with an essential region from the ade-
novirus genome; pHelper, Stratagene, La Jolla, CA) at a ratio of 1:1:226,27 in 
serum-free medium and GlutaMAX-І (1×; Gibco Life Technologies, Grand 
Island, NY) using polyethyleneimine (Polyethyleneimine Max, Polysciences) 
at a DNA:polyethyleneimine ratio of 1:219 for 5 days. The cis AAV vector 
plasmid expressing the EGFP gene under the control of the CBA promoter, 
pdsAAV-CB-EGFP, was used in this study (provided by Dr. Arun Srivastava, 
University of Florida). Subsequently, the cells were cotransfected with the 
three plasmids (90.1 µg of the helper plasmid, 44.8 µg of the trans-plasmid, 
and 44.8 µg of the cis plasmid per square dish) in serum-free medium and 
GlutaMAX-І with polyethyleneimine; the medium was not replaced for 5 
days. As most rAAV1 particles were obtained directly in the culture super-
natant,18,20 they were harvested from the culture supernatant at 120 hours 
after transfection. After filtration through a 0.45-µm filter, the culture super-
natant was ultrafiltrated with TFF and concentrated about 10 times using 
a hollow fiber (UFP-750-E-3MA, 750,000 nominal molecular weight cutoff, 
GE Healthcare, Westborough, MA) with the KrosFlo Research IIi TFF system 
(Spectrum Laboratories, Rancho Dominguez, CA). Subsequently, 1 µl/5 ml of 
benzonase (250 U/µl, Merck Millipore, Billerica, MA) was added to the sample 
and incubated for 30 minutes at 37 °C. After stopping the benzonase reac-
tion with 0.5 mol/l ethylenediaminetetraacetic acid, the crude rAAV1 frac-
tions were heated for 20 minutes at 50 °C, and the denatured low-molecular-
weight proteins were removed with three cycles of centrifugation at 13,000g 
for 10 minutes. After reducing protein debris by 1/3-saturated AS precipita-
tion (adding half the sample volume of saturated AS made the final solution 
33% (NH4)2SO4), rAAV1 was finally precipitated in the 1/2-saturated AS solu-
tion (added half the original sample volume of saturated AS) (1/3→1/2 AS). 
Subsequently, the precipitated rAAV1 was dissolved in 10 ml of PBS (+) (in 3 
mmol/l MgCl2, Sigma-Aldrich).
Figure 6 Comparison of the purity of recombinant adeno-associated 
virus serotype 1 (rAAV1) obtained from ultracentrifugation and 
chromatography-based purification. (a) The purity of rAAV1 obtained 
by ultracentrifugation was analyzed by 5–20% gradient sodium 
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) gel. 
Post-tangential flow filtration preparation was directly precipitated in 
1/2-saturated ammonium sulfate (AS). Subsequently, the 1/2-saturated 
AS-precipitated sample was ultracentrifuged for 15 hours, 16 minutes 
at 125,400g with an iodixanol linear gradient. The proteins were stained 
by Quick Coomassie Brilliant Blue. rAAV1 was fractionated from the 
bottom. Lane number corresponds to fraction number. For example, 
lane 3 shows the fraction 3. The black square shows the peak fractions of 
rAAV1. Lanes 1–7: Fr 1–7; M: protein size marker. (b) The purity of rAAV1 
using this novel protocol on SDS–PAGE gel (Oriole staining). The three 
rAAV1 capsid proteins, VP1 (81.4 kDa), VP2 (66.2 kDa), and VP3 (59.6 kDa), 
were represented.
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Various methods attempted to remove 200 kDa protein impurities
All methods were assayed post-TFF preparation. First, the sample was heated 
at 50 °C for 20 minutes. Second, ultrafiltrated by Vivaspin 6 300,000 MWCO 
PES and 1000,000 MWCO PES (Sartorius AG) at 500g for 10 minutes. Third, 
precipitated by acetone. After adding four times volumes of acetone, the 
sample was incubated at −80 °C for 1 hour. After centrifugation at 13,000g 
for 15 minutes, the supernatant was removed and the pellet was dissolved 
in PBS. Fourth, treated with Novec 7100 (3M, St. Paul, MN). Novec treatment 
is similar to chloroform extraction. After the same quantity of Novec was 
added to the sample, the sample was voltexed and centrifuged at 18,800g 
for 15 minutes. Subsequently, the water layer and the middle layer were col-
lected and dissolved in PBS.
Ion-exchange and gel-filtration chromatography
Initially, the resultant rAAV1 sample was dialyzed against 20 mmol/l Tris–HCl 
(pH 8.0) buffer containing 50 mmol/l NaCl and 3 mmol/l MgCl2
17 for 3–4 
hours. In the next step, the rAAV1 dialysate was dialyzed against 20 mmol/l 
Tris–HCl (pH 8.0) buffer containing 5 mmol/l NaCl and 3 mmol/l MgCl2 
(dialysis buffer) for 20 hours with one fresh buffer replacement. The sample 
was then diluted with dH2O until the conductivity decreased to around 1.0 
mSV/cm. The conductivity was measured with an electroconductivity sen-
sor (LAQUA Twin, HORIBA, Tokyo, Japan). The diluted sample was loaded 
at a rate of 1 ml/minute to tandem five cation-exchange membranes and 
five anion-exchange membranes with a column volume of 0.86 ml (Acrodisc 
unit with Mustang SXT and the Mustang QXT membrane, Pall Corporation, 
Ann Arbor, MI) equilibrated with the equilibration buffer which was diluted 
dialysis buffer with dH2O (conductivity = 1.2 mSV/cm) by a syringe pump 
(TERUMO, Tokyo, Japan). The membrane was washed with over 10 column 
volumes of wash buffer which was diluted dialysis buffer with dH2O (con-
ductivity = 1.0 mSV/cm). After removing the Mustang SXT columns, rAAV1 
was eluted from the Mustang QXTs using 120 ml of 100 mmol/l NaCl, 120 
mmol/l NaCl, 130 mmol/l NaCl, 140 mmol/l NaCl, and 200 mmol/l NaCl in 20 
mmol/l Tris–HCl (pH 8.0) buffer with 3 mmol/l MgCl2. All of the 120 mmol/l 
NaCl-containing buffer and the first 40 ml sample of the elution with 130 
mmol/l NaCl in 20 mmol/l Tris–HCl (pH 8.0) buffer with 3 mmol/l MgCl2 were 
used for gel-filtration chromatography, at next purification step.
After ultrafiltration with Ultracel 30 K (Merck Millipore, Tullagreen, Ireland) 
and buffer exchange (PBS(+)), rAAV1 was finally purified by size-exclusion 
chromatography (gel-filtration chromatography) on the Superdex 200 
10/300 GL system using the AKTÄ Explorer 100 HPLC (GE Healthcare, Little 
Chalfont, UK) system equipped with a 2 ml sample loop with 3.3 mmol/l 
morpholinoethanesulfonic acid, 3.3 mmol/l HEPES, and 3.3 mmol/l sodium 
acetate buffer (MHN, pH 6.5) containing 300 mmol/l NaCl and 0.01% non-
ionic surfactant Pluronic F-68 (Gibco, Invitrogen, Grand Island, NY); 0.5 ml 
fractions were collected.
Peak fractions based on 280 nm absorption were collected and ultrafil-
trated with Ultracel 30 K. The genomic titer was determined by quantitative 
PCR. The biological activity (infectious titer) was determined by transduc-
tion to C2C12 cells and evaluating the cells for EGFP positivity. The purity of 
the final rAAV1 product was assessed by SDS–PAGE and western blotting. 
The contents of empty particle contamination of the final rAAV1 were deter-
mined by electron microscopy.
Quantitative PCR
Two microliters of benzonase (250 U/µl) was added to the purified rAAV1 
for 30 minutes. After stopping the reaction with the addition of 0.5 mol/l 
ethylenediaminetetraacetic acid and 1× Tris–ethylenediaminetetraacetic 
acid, the lysis buffer (AL Buffer, QIAGEN, Hilden, Germany) was added to 
extract the viral genome and was heated at 56 °C for 10 minutes. After 
dilution by 100-fold with dH2O, the benzonase-resistant genome titer was 
measured by SYBR green dye real-time Q-PCR (7500 Fast Real-Time PCR 
System, Applied Biosystems, Foster City, CA) using an EGFP-targeted primer 
(forward primer: 5′-AGCAGCACGACTTCTTCAAGTCC-3′, reverse primer: 
5′-TGTAGTTGTACTCCAGCTTGTGCC-3′). We used a linearized pdsCBA-EGFP 
DNA (digestion by SacІ restriction enzyme) as a standard plasmid. After 95 
°C holding stage for 10 seconds, two-step PCR cycling stage was performed 
at 95 °C for 5 seconds, followed by 60 °C for 34 seconds for 40 cycles.
SDS–PAGE and western blotting analysis
Purified rAAV1 was separated on 5–20% gradient polyacrylamide gels (Wako, 
Osaka, Japan) with SDS running buffer. Oriole Fluorescent Gel Stain (BIO-
RAD, Hercules, CA) or Quick Coomassie Brilliant Blue (Wako) was applied to 
visualize and analyze the SDS–PAGE bands.
For western blotting analysis, the samples were transferred to a polyvi-
nylidene fluoride membrane overnight. After transfer, the membrane was 
blocked with 3% bovine serum albumin/Tris-buffered saline with Tween 20 
and incubated with the primary antibody (monoclonal antibody B1; Progen, 
Heidelberg, Germany) for 1 hour. After rinsing with Tris-buffered saline with 
Tween 20, the membrane was probed with horseradish peroxidase-labeled 
anti-mouse secondary antibody (GE Healthcare, Little Chalfont, UK). The pro-
tein was detected using the ECL Plus Western Blotting Detection System (GE 
Healthcare, Buckinghamshire, UK).
The biological activity (infectious titer)
The 2.0 × 105 of C2C12 cells were transduced with rAAV1 at 0.5, 0.7, and 
2.0 × 105 v.g./cell. Population of EGFP-positive cells as well as intensity was 
measured by fluorescence-activated cell sorting (FACSCalibur, Becton, 
Dickinson and Company, Franklin Lakes, NJ) with propidium iodide staining 
solution (Immunostep, Salamanca, Spain) to remove nonviable cells.
Electron microscopy
A carbon-stabilized copper grid (Nisshin EM Corporation, Tokyo, Japan) was 
placed onto a sample and incubated for 1 minute. The sample on the grid 
was then negatively stained for 1 minute with 1% uranyl acetate. Finally, the 
grid was viewed with the H-7650 transmission electron microscope (Hitachi, 
Tokyo, Japan) at an accelerating voltage of 80 kV. The ratio of empty particles 
to encapsidated particles was determined by counting the number of pack-
aged and unpackaged particles in the electron micrographs. We investi-
gated 11 fields on electron microscopy.
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